Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic anti­gens

It felt nat­ur­al for Alain Maiore and Se­bas­t­ian Amigore­na to bring in Michel Sade­lain as a co-founder of Mnemo Ther­a­peu­tics. A CAR-T pi­o­neer, Sade­lain had been in­volved as an ad­vi­sor since the ear­ly days — en­thu­si­as­tic about Amigore­na’s work in a ge­net­ic knock­out that could en­hance T cell mem­o­ry and a new class of po­ten­tial tar­gets he’s dis­cov­ered — and could in­tro­duce some well-known tech­nolo­gies to the tool­box. So they got the ini­tial cash from Sofinno­va Part­ners to plant roots in Paris and New York in ear­ly 2019; with­in a few months, they be­gan to see more clear­ly just what the anti­gen dis­cov­ery plat­form might un­lock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER